Podiatrists in Wakefield, RI Accepting Medicare

8 Podiatrists found. Showing 1 - 8

Eric D Meehan, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 70 Kenyon Ave, Ste 212, Wakefield, RI 02879 Phone: 401-354-7966

South County Podiatry Associates, Inc. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 70 Kenyon Ave, Suite 212, Wakefield, RI 02879 Phone: 401-789-8912    Fax: 401-782-8702

John C Zervos, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 70 Kenyon Ave, South County Medical Office Building Suite #212, Wakefield, RI 02879 Phone: 401-789-8912    Fax: 401-782-8702

Shoreline Podiatry, Llc Podiatrist - Foot & Ankle Surgery Medicare: Not Enrolled in Medicare Practice Location: 24 Salt Pond Rd, Unit E-1, Wakefield, RI 02879 Phone: 401-783-2424    Fax: 401-789-2095

Eleni T Pappas, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 70 Kenyon Ave, South County Medical Office Building Suite #212, Wakefield, RI 02879 Phone: 401-789-8912    Fax: 401-782-8702

Shoreline Podiatry, Inc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 24 Salt Pond Rd, Unit E-1, Wakefield, RI 02879 Phone: 401-783-2424    Fax: 401-789-2095

Dr. Eric Jason Buchbaum, DPM Podiatrist - Foot Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 High St, Wakefield, RI 02879 Phone: 401-789-1422    Fax: 401-782-6810

Dr. James Mccormick, DPM Podiatrist - Foot Surgery Medicare: Accepting Medicare Assignments Practice Location: 24 Salt Pond Rd, Unit E1, Wakefield, RI 02879 Phone: 401-783-2424    Fax: 401-789-2095

News Archive

Zytiga is commonly prescribed for second-line treatment of mCRPC patients

Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain, and the United Kingdom (EU5).

Public-private partnership will promote handwashing to help reduce child mortality in Africa

Though the number of children dying of preventable and treatable diseases worldwide has dropped significantly since 1990, there is "realistic hope for much more" progress, particularly if "improved hygiene and sanitation ... play a key role in the next stage," Jeffrey Sachs, director of the Earth Institute at Columbia University, and Paul Polman, CEO of Unilever, write in the Huffington Post's "Global Motherhood" blog.

New clinical trial may help reduce radiation dose for patients with HPV-positive oropharyngeal cancer

Researchers from Fox Chase Cancer Center and other institutions have completed a phase II clinical trial that may help identify those patients with HPV-positive oropharyngeal cancer who do not require the full radiation dose given in a standard regimen of Intensity-Modulated Radiation Therapy (IMRT). Preliminary findings will be presented by Shanthi Marur, first author on the study and an oncologist at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, at the 49th Annual Meeting of the American Society of Clinical Oncology on Sunday, June 2.

MAKO Surgical second-quarter total revenue increases 151% to $10.3 million

MAKO Surgical Corp., a medical device company that markets both its RIO® Robotic Arm Interactive Orthopedic surgical platform and proprietary RESTORIS® implants for minimally invasive orthopedic knee procedures known as MAKOplasty®, today announced its operating results for its second quarter ended June 30, 2010.

Read more Medical News

› Verified 4 days ago